Difference between revisions of "Teaching Points"
Jump to navigation
Jump to search
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
* [[DL vs. VL]] | * [[DL vs. VL]] | ||
* [[Methadone]] | * [[Methadone]] | ||
| − | * [[Low vs. High FiO2]] | + | * Extubation strategy [[Low vs. High FiO2]] |
| + | * Esmolol vs Fentanyl induction | ||
| + | * [[Weight scalars]] | ||
| + | * Tachycardia and Bradycardia algorithms | ||
| + | * Airway anatomy | ||
| + | * Stanpumpr.io / Posology | ||
| + | * Sustainability priorities (N2O, HVAC, LFA, disposable items) | ||
* pEEG | * pEEG | ||
* Ketorolac 15 vs. 30 | * Ketorolac 15 vs. 30 | ||
* Modified Bier block for propofol infusion pain | * Modified Bier block for propofol infusion pain | ||
* Permissive hypercapnia | * Permissive hypercapnia | ||
| + | * [https://pmc.ncbi.nlm.nih.gov/articles/PMC12998346/ Remimazolam targets]: the theoretical initial target concentration of remimazolam may be 0.1 µg/mL for light sedation, 0.2 µg/mL for moderate sedation, and 0.3 µg/mL for deep sedation in elderly patients (70 years), and 1.5 or 2 times those concentrations in middle-aged (45 years) or young adult (20 years) patients. Dose adjust upwards by 10% in females, down by 20% in obesity or ASA III/IV. | ||
Latest revision as of 13:11, 16 October 2026
- DL vs. VL
- Methadone
- Extubation strategy Low vs. High FiO2
- Esmolol vs Fentanyl induction
- Weight scalars
- Tachycardia and Bradycardia algorithms
- Airway anatomy
- Stanpumpr.io / Posology
- Sustainability priorities (N2O, HVAC, LFA, disposable items)
- pEEG
- Ketorolac 15 vs. 30
- Modified Bier block for propofol infusion pain
- Permissive hypercapnia
- Remimazolam targets: the theoretical initial target concentration of remimazolam may be 0.1 µg/mL for light sedation, 0.2 µg/mL for moderate sedation, and 0.3 µg/mL for deep sedation in elderly patients (70 years), and 1.5 or 2 times those concentrations in middle-aged (45 years) or young adult (20 years) patients. Dose adjust upwards by 10% in females, down by 20% in obesity or ASA III/IV.